Early trial pairs approved and experimental drugs to fight inherited breast cancer
NCT ID NCT03641755
Summary
This early-stage study is testing the safety and finding the right dose of a two-drug combination for people with advanced breast cancer linked to a BRCA gene mutation. It combines an approved drug (olaparib) with an experimental one (sapacitabine). The goal is to see if this combination can help control the cancer's growth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Broad Institute of MIT
Cambridge, Massachusetts, 02142, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
Conditions
Explore the condition pages connected to this study.